In an adult with chronic low back pain refractory to NSAIDs, physical therapy, and activity modification, what is the role of nortriptyline compared to amitriptyline in management?

Nortriptyline and Amitriptyline Have Limited and Equivalent Efficacy for Chronic Low Back Pain

Neither nortriptyline nor amitriptyline should be first-line therapy for chronic low back pain refractory to NSAIDs and physical therapy, but if a tricyclic antidepressant is chosen, nortriptyline is preferred over amitriptyline due to equivalent analgesic efficacy with better tolerability and fewer anticholinergic side effects.

Evidence-Based Rationale

Guideline Recommendations Place TCAs as Third-Line Options

The 2017 American College of Physicians guidelines 1 explicitly recommend a stepwise approach for chronic low back pain:

• First-line: Nonpharmacologic therapy (exercise, multidisciplinary rehabilitation, acupuncture, cognitive behavioral therapy)
• Second-line pharmacologic: NSAIDs first, then tramadol or duloxetine (not traditional TCAs)
• Third-line: Opioids only after failure of above treatments

The systematic review supporting these guidelines 2 found that antidepressants as a class showed only small to moderate, primarily short-term effects on pain. Notably, duloxetine was specifically identified as effective for chronic low back pain, while traditional tricyclics like amitriptyline and nortriptyline were not highlighted as preferred agents.

Direct Comparison: Nortriptyline vs Amitriptyline

When comparing these two tricyclics specifically:

Equivalent Analgesic Efficacy:

• A 2014 prospective study in neuropathic pain 3 demonstrated that amitriptyline and nortriptyline produced equivalent pain reduction (23-26% on visual analog scale) with similar discontinuation rates (26-37%)
• A 1998 randomized trial in postherpetic neuralgia 4 found no difference in pain relief between the two drugs for steady, brief, or skin pain

Superior Tolerability of Nortriptyline:

• The 2014 study 3 found that while overall adverse effects were similar, weight gain was more common with amitriptyline, whereas nortriptyline caused more dry mouth
• The 1998 trial 4 reported that intolerable side effects were more common with amitriptyline
• Recent 2026 observational data 5 showed amitriptyline caused more drowsiness (7.9%) compared to duloxetine, with dry mouth being common in both

Limited Evidence Specifically for Low Back Pain

Critical limitation: The evidence for TCAs in low back pain specifically is weak:

• A 1998 placebo-controlled trial of nortriptyline 6 showed only modest pain reduction (22% vs 9% on placebo, P=0.050) in chronic low back pain without depression
• A 2007 study 7 found that nortriptyline, morphine, and their combination had limited effectiveness in chronic sciatica, with high dropout rates
• A small 2010 retrospective review 8 suggested benefit in lumbar spinal stenosis, but this was uncontrolled

Clinical Algorithm

For chronic low back pain refractory to NSAIDs and physical therapy:

1. Prioritize duloxetine (60 mg daily) as the antidepressant of choice based on ACP guidelines 1 - it has stronger evidence for chronic low back pain than traditional TCAs

2. If duloxetine is contraindicated or not tolerated, and a TCA is being considered:

   • Choose nortriptyline over amitriptyline due to better tolerability 3, 4
   • Start with 10-25 mg at bedtime 9, 8
   • Titrate gradually to 50-100 mg daily based on response
   • Target plasma levels of 50-150 ng/mL if monitoring available 9
   • Expect only modest benefit (approximately 20-25% pain reduction) 6

3. Monitor closely for:

   • Anticholinergic effects (dry mouth, constipation, urinary retention) - more common with amitriptyline 9, 3
   • Sedation and drowsiness
   • Cardiac conduction abnormalities, especially in elderly or those with cardiovascular disease 9
   • Suicidality, particularly in first few months 9

Important Caveats

• Depression is not required: The 1998 nortriptyline trial 6 showed pain relief occurred without antidepressant effect in non-depressed patients, suggesting noradrenergic mechanisms for analgesia
• Elderly patients: Use lower doses (30-50 mg daily divided) and monitor for higher plasma levels of active metabolites 9
• Discontinuation is common: Expect 26-37% of patients to discontinue due to inefficacy or adverse effects 3
• Not FDA-approved: Neither TCA is FDA-approved for low back pain; this is off-label use 9
• Contraindications: Avoid in patients with recent myocardial infarction, glaucoma, urinary retention, or untreated hyperthyroidism 9

The evidence strongly suggests that if you've already tried NSAIDs and physical therapy without success, duloxetine should be the next antidepressant choice rather than traditional TCAs. However, when choosing between nortriptyline and amitriptyline specifically, nortriptyline's better side effect profile makes it the preferred option despite equivalent modest analgesic effects.